|
Alzheimer Disease
Citations 271-280 of 489 total displayed.
|
Past content
(since Jan 1998):
|
- Original Contributions
When Sporadic Disease Is Not Sporadic: The Potential for Genetic Etiology
- Jill S. Goldman; Bruce L. Miller; Jiri Safar; Sunita de Tourreil; Jennifer L. Martindale; Stanley B. Prusiner; Michael D. Geschwind
Arch Neurol 2004; 61: 213-216.
[Abstract]
[Full text]
[PDF]
- Original Contributions
The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial
- Murray A. Raskind; Elaine R. Peskind; Luc Truyen; Paul Kershaw; ChandrasekharRao Venkata Damaraju
Arch Neurol 2004; 61: 252-256.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials
- Michael Grundman; Ronald C. Petersen; Steven H. Ferris; Ronald G. Thomas; Paul S. Aisen; David A. Bennett; Norman L. Foster; Clifford R. Jack Jr; Douglas R. Galasko; Rachelle Doody; Jeffrey Kaye; Mary Sano; Richard Mohs; Serge Gauthier; Hyun T. Kim; Shelia Jin; Arlan N. Schultz; Kimberly Schafer; Ruth Mulnard; Christopher H. van Dyck; Jacobo Mintzer; Edward Y. Zamrini; Deborah Cahn-Weiner; Leon J. Thal
Arch Neurol 2004; 61: 59-66.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Cognitive Reserve–Mediated Modulation of Positron Emission Tomographic Activations During Memory Tasks in Alzheimer Disease
- Nikolaos Scarmeas; Eric Zarahn; Karen E. Anderson; Lawrence S. Honig; Aileen Park; John Hilton; Joseph Flynn; Harold A. Sackeim; Yaakov Stern
Arch Neurol 2004; 61: 73-78.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements: The Cache County Study
- Peter P. Zandi; James C. Anthony; Ara S. Khachaturian; Stephanie V. Stone; Deborah Gustafson; JoAnn T. Tschanz; Maria C. Norton; Kathleen A. Welsh-Bohmer; John C. S. Breitner
Arch Neurol 2004; 61: 82-88.
[Abstract]
[Full text]
[PDF]
- Editorials
Metal Chelation Therapy for Alzheimer Disease
- Roger N. Rosenberg
Arch Neurol 2003; 60: 1678-1679.
[Extract]
[Full text]
[PDF]
- Original Contributions
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting A Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial
- Craig W. Ritchie; Ashley I. Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E. Tanzi; Colin L. Masters
Arch Neurol 2003; 60: 1685-1691.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Cerebrospinal Fluid Tau and -Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?
- Christopher M. Clark; Sharon Xie; Jesse Chittams; Douglas Ewbank; Elaine Peskind; Douglas Galasko; John C. Morris; Daniel W. McKeel Jr; Martin Farlow; Sharon L. Weitlauf; Joseph Quinn; Jeffrey Kaye; David Knopman; Hiroyuki Arai; Rachelle S. Doody; Charles DeCarli; Susan Leight; Virginia M.-Y. Lee; John Q. Trojanowski
Arch Neurol 2003; 60: 1696-1702.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Stroke and the Risk of Alzheimer Disease
- Lawrence S. Honig; Ming-Xin Tang; Steven Albert; Rosanne Costa; Jose Luchsinger; Jennifer Manly; Yaakov Stern; Richard Mayeux
Arch Neurol 2003; 60: 1707-1712.
[Abstract]
[Full text]
[PDF]
- Original Contributions
Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type: A 2-Year Follow-up Study
- Barbara Borroni; Francesca Colciaghi; Carlo Caltagirone; Luca Rozzini; Laura Broglio; Flaminio Cattabeni; Monica Di Luca; Alessandro Padovani
Arch Neurol 2003; 60: 1740-1744.
[Abstract]
[Full text]
[PDF]
|
|
